Lead Sponsor

Santhera Pharmaceuticals

Age

All ages

Sex

ALL

Healthy Volunteers

No

•Patients who completed the LEROS study, who attended the end of study visit in LEROS and who in the opinion of investigator could benefit from continuation of idebenone treatment.
•Signed and dated Informed Consent Form (to be obtained at the Enrollment Visit from patient or parent/legal guardian (if applicable) prior to dispensing idebenone to the patient).

•Patients who, in the opinion of the LEROS investigator, had unacceptable tolerability of idebenone treatment in LEROS trial.
•Patients who prematurely discontinued the LEROS study.

Related studies

NCT07258667 · Leber Hereditary Optic Neuropathy (LHON), Leber's Hereditary Optic Neuropathy (LHON), and more

NCT02771379 · Leber's Hereditary Optic Neuropathy (LHON)

NCT02300753 · Leber's Hereditary Optic Neuropathy

Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study